Can't argue with those points. I'll add that market sentiment on biotech has taken a significant downturn. All due to so many people losing truckloads of money on companies with drugs that didn't have a chance in the Covid space and which failed miserably. Cytodyn is seen in the same light.

The saving grace for Cytodyn is once we have success people may finally realize the broad scope of what leronlimab can do and the amazing potential.

ps. Generating revenue means little if that revenue is little. I was in AGRX right before it was due for approval but I was going to dump it right after the rise after approval because I knew it would have limited prescriptions. Of course the FDA screwed then by making them do an adhesive test for their patch. I was also in VSTM before approval figuring a last chance drug would gain traction. It didn't, when I sold that out to buy more CYDY they had 25 prescriptions.